Pharmaceutical and agricultural conglomerate Bayer is engaged in a two-pronged legal battle in the United States, aiming to prevent the transfer of settlement funds from its high-profile Roundup weedkiller litigation to third-party litigation funders. The German-headquartered company, which acquired Monsanto and its controversial Roundup product in 2018, is pursuing its objections in both federal and state courts, citing concerns that such transfers could impede its ongoing efforts to resolve a vast number of outstanding claims.
The core of Bayer's argument centres on the potential for these third-party agreements to complicate and prolong the settlement process. Litigation funders, who invest in lawsuits in exchange for a share of any eventual payout, are increasingly common in large-scale legal actions. However, Bayer contends that allowing these entities to claim portions of settlement funds could make it more difficult to reach comprehensive resolutions with claimants directly, potentially increasing the overall cost and complexity of the litigation.
The legal challenges stem from thousands of lawsuits alleging that Roundup, a glyphosate-based herbicide, causes non-Hodgkin lymphoma. Since its acquisition of Monsanto, Bayer has faced immense financial and reputational pressure due to this litigation, leading to significant settlement agreements. The company has already committed billions of US dollars to resolve a substantial portion of these claims, but a significant number remain.
Bayer's strategy involves challenging the validity and enforceability of the agreements between claimants and litigation funders. By doing so, the company hopes to maintain more direct control over the settlement process and ensure that funds are distributed efficiently to affected individuals. The outcomes of these legal challenges could set important precedents for how large-scale mass tort settlements are managed, particularly concerning the role of external funding.
The ongoing legal manoeuvring highlights the intricate financial and legal landscape surrounding mass tort litigation. For a company like Bayer, which operates globally and has a significant presence in the UK market through its various divisions, the efficient resolution of such large-scale legal issues is crucial for its financial stability and long-term strategic planning. The company's share price has been significantly impacted by the Roundup litigation in recent years.